drugset
drugset / Trial / NCT01458392

Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck

NCT01458392 ↗

Phase 2 Completed 46 enrolled Acceleron Pharma, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Dalantercept, a soluble form of the activin receptor-like kinase-1 protein, is being studied in patients with squamous cell carcinoma of the head and neck (SCCHN). Dalantercept blocks the development of blood vessels that supply tumors.

Timeline

Start
2011-10
Primary completion
2015-06
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalantercept Protein / enzyme biologic — Subcutaneous

Indications

head and neck squamous cell carcinoma